Financial Results | Johnson & Johnson 2025 Q3 Cumulative Revenue USD 69629.00 Million Net Income USD 21688.00 Million

Johnson & Johnson(JNJ) posted the Q3 of its 2025 financial results on 10/22/2025, reporting total revenue of USD 69629.00 million in the first three quarters, up 5.02% from USD 66301.00 million year over year, reporting net income of USD 21688.00 million in the first three quarters, up 103.93% from USD 10635.00 million year over year. The EPS is USD 9.01 in the first three quaters, compare with USD 4.42 last period.

[Detailed Data]

Million USD	Q3 2025	Q2 2025	Q1 2025	Q4 2024
Total Revenue	23993.00	23743.00	21893.00	22520.00
Cost of Sales	7303.00	7628.00	7357.00	7128.00
Gross Profit	16690.00	16115.00	14536.00	15392.00
Total Operating Expenses	9612.00	9453.00	8209.00	11624.00
Operating Income	7078.00	6662.00	6327.00	3768.00
Net Income	5152.00	5537.00	10999.00	3431.00
Net Income Attributable to Common Shareholders	5152.00	5537.00	10999.00	3431.00
EPS(USD)	2.14	2.3	4.57	1.4251

[Company Profile]
Johnson & Johnson was incorporated in the State of New Jersey in 1887. Johnson & Johnson and its subsidiaries have engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company's primary focus is products related to human health and well-being. The Company is organized into two business segments: Innovative Medicine and MedTech.